Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;37(5):981-987.
doi: 10.1038/s41375-023-01859-3. Epub 2023 Apr 19.

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group

William Shomali  1 , Philomena Colucci  2 , Tracy I George  3 , Jean-Jacques Kiladjian  4 , Cheryl Langford  1 , Jay L Patel  3 , Andreas Reiter  5 , Alessandro M Vannucchi  6 , Jason Gotlib  7
Affiliations
Review

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group

William Shomali et al. Leukemia. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

WS has received research support from Incyte Corporation and Blueprint Medicines; has received consultancy fees from or participated on advisory boards for Blueprint Medicines and Incyte Corporation. PC is a former employee and stock owner of Incyte Corporation. TIG has received consultancy fees from or participated on advisory boards for Blueprint Medicines, Celgene/Bristol Myers Squibb, Cogent Biosciences, and Incyte Corporation. J-JK is a member of an entity’s Board of Directors or advisory committees for AbbVie, AOP Health, Bristol Myers Squibb, Incyte Corporation, and Novartis. CL has received consultancy fees from Blueprint Medicines, Cogent Biosciences, and Incyte Corporation. JLP has received consultancy fees from or participated on advisory boards for Astellas Pharma, Celgene/Bristol Myers Squibb, and Incyte Corporation. AR has received honoraria from, is a member of an entity’s Board of Directors or advisory committees for, and received other (travel expenses) and research funding from AOP Health, Blueprint Medicines, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Novartis; is a member of an entity’s Board of Directors or advisory committees and received research funding from AbbVie; and received honoraria and other (travel expenses) from Incyte Corporation. AMV received honoraria from and is a member of an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Incyte Corporation, and Novartis; and is a member of an entity’s Board of Directors or advisory committees for AbbVie. JG received research funding from Blueprint Medicines, Deciphera, and Incyte Corporation; received consultancy fees from or participated on advisory boards for Allakos, Blueprint Medicines, Deciphera, Incyte Corporation, and Novartis.

Figures

Fig. 1
Fig. 1. FGFR1 fusion partners.
Sixteen fusion partners of FGFR1 have been currently characterized. Chromosome breakpoints for the fusion partners are shown below each partner gene. ZMYM2 on chromosome 13q12 and BCR on chromosome 22q11 are the most common fusion partner genes of FGFR1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, 2. Lyon, France: International Agency for Research on Cancer; 2017.
    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. doi: 10.1182/blood.2022015850. - DOI - PMC - PubMed
    1. Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard KK, Craig FE, et al. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2021;155:160–78. doi: 10.1093/ajcp/aqaa208. - DOI - PubMed
    1. Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, et al. Myeloid/Lymphoid neoplasms with Eosinophilia and TK fusion genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2020;18:1248–69. doi: 10.6004/jnccn.2020.0042. - DOI - PubMed

Publication types

Substances